...The poster presentation will discuss additional subgroup analyses on a combined dataset from two pivotal Phase 3 clinical trials in 1,732 patients suffering from erectile dysfunction ("ED"). The data further demonstrates the efficacy and safety of Vitaros® as an easy-to-administer, topical first-line treatment option for all ED patients, independent of age, body mass index ("BMI") and risk factors, such as cardiovascular disease and diabetes.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.